Healthcare News 14

• "Are my medical records protected, Doctor?"
• "Tamper-Proof" -- A Significant Gain to Whom??
• $10 billion Propsal for National Institues of Health
• $144.4 Billion for Healthcare in Economic Stimulus Package
• “You've got to be very careful if you don't know where you are going, because you might not get there.” Yogi Berra
• 16.2% of GDP for health care??
• 300 patients with the disorder, and the cost will be????
• 7,000 ER Visits per year from Children's Cold and Cough Medicines
• A Challenge for Alcon R&D - Integration with Novartis
• A closer look
• A flawed analysis that is unlikely to have as large an impact as financial pressure to prescribe generic simvastatin
• A Formula for Cardiovascular Toxicity: Dose/Duration Therapy in the Elderly
• A New Ray of Hope from $10B for New NIH- from Dr Sanjeev Davey
• A Pill For Every Mouth
• A Recipe for Overuse of Anti-influenza Drugs
• A Rituxumab Wanna be?
• A target may well decrease the market for EGFR inhibitors (Erbitux & Vectibix) in colon cancer (CRC)
• A timely and modern alternative to the squeeze women dread.
• A welcome improvement
• Acceptance of genetically engineered foods is 0. Do they really believe the public will accept food irradiation?
• Accuracy?
• Accuray Cyberknife Sales About to Go Through The Roof
• Acorda Therapeutic's Fampridine SR for Ambulation in MS Reported in The Lancet
• Acquisitions of Indian Pharma on the extended horizon by Brand name pharma
• Affymetrix Comples Acquisition of Panomics
• Algeta completes comprehensive phase II clinical program with Alpharadin for treating bone metastases in patients with advanced prostate cancer
• Alimta potential In India
• Amiodarone is here to stay.
• An Unfortunate Victory for EU Repackagers
• Analysts Underestimate the Impact of the Recession on Device Manufacturers
• Another Alleged Association
• Antidepressants Vary More in Side Effects, Not Efficacy
• Apidra for Diabetes: No much innovation but will get some use
• Appendicitis Diagnostic Technology Receives Notice of Allowance
• Approval Likely
• Are all statins equal ?
• Are nexavar prescriptions increasing?
• Array-Based Service Companies Plan for Growth
• As predicted the genomic revolution marches on!
• Asthma - will this help??
• Astra Zeneca Seeking to Widen Indications, Markets for Seroquel XR
• AstraZeneca and Targacept study of cognitive enhancer- potential for use in ADHD
• Aurobindo terbinafine approval- what effect will this have?
• Aurobindo's Terbinafine Tablets? Not a news maker
• Autism and Rainfall, Milk and Cancer: Correlation Is Not Causation !
• Autism linked to rainfall? Doubtful
• Autism, the universal disorder
• Avastin and clots? News to me. Black box warning? Why?
• Avastin for GBM: modest efficacy and soon to be approval
• Avastin in Glioblastomas: I believe approval will be....
• Avastin Likely To Be Rapidly Adopted for Treatment of Glioblastoma
• Avastin Raises Risk of Clots: New News?
• AXX100
• AZX100: an HSP20 mimic for smooth muscle relaxation in keloid myofibroblasts
• Beckman Coulter Buys Olympus Diagnostics
• Big Pharma will continue to thrive in new administration, but not insurnace companies
• Black Box warning un-neccesary-Read the "fine Print"!!!
• blood microRNA testing for cancer
• BMS & Exelixis: A bargain?? The cost appears high?
• Bold Contest for a Daunting Problem
• Boosting brain function in healthy people- this is no free lunch
• Brain enhancement - what are the implications?
• Breast Cancer Breakthrough
• Breast Cancer Gene Study Findings
• Breast Cancer Predictive Tool
• Breast Cancer Technology from bioTheranostics
• Breast Cancer Test from Clarient, Inc.
• Breast Cancer Test from DiaGenic ASA
• Breast Cancer Test Shows Expanded Use in Early Study
• Breast Cancer Test Shows Promise
• Bullish on the Growth of this Therapeutic Sector
• C. difficile An Underestimated Problem
• C. difficile infection not neccesarily related to antibiotics.
• C. difficile not linked to antibiotics will change how I order stool studies
• Canada Joins US Groups in Calling for Greater Genetic Testing Oversight
• Cancer Diagnostics from Rosetta Genomics Ltd.
• Cardinal Health Rebuilds Reputation with DEA Compliance Efforts
• Cataract Surgery Option Still Falls Short
• Caution in drawing conclusions
• Celebrex and Heart Attacks - Nexium and Plavix combination.
• Certainly it is true that Medicare can control price of cancer drugs limitedly
• Cervical Cancer License Agreement Between Arbor Vita and BD
• Cervical Cancer Point of Care Test
• Cheating Generic Competition Invites Big Brother and Oversight
• Christmas in February: President Obama Likely to Approve $19 billion for Health IT
• Clinical trials and genetic studies the fad but only part of the answer.
• Clinical trials held abroad... Implications?
• Colon Cancer Screening without Radiation
• Colorectal Cancer Molecular Diagnostics
• Colorectal Cancer Test from Exiqon
• Colorectal Cancer Test Requires Simple Blood Sample
• Combination Vaccines: Good for kids but not-so-good for providers?
• Commonwealth Fund Ratings of Hospitals is a Step in the Right Direction
• Computer Technology Really Does Improve Patient Care
• Congressional Leader Wants Major Upfront Governmental Health IT Investment
• Conmed Under-performance is a Foreshadowing of Things to Come
• Cord blood banking may be a parent's insurance policy with few filed claims
• Cord Blood Cell Banking: Too far ahead of the stem cell science behind it?
• Could Electronic Health Record Databases Make Clinical Trials Unnecessary?
• Crestor's results in the Jupiter Study likely to change medical-economic perspectives in statin choices.
• CSL Gets FDA Approval for Its RiaSTAP Fibrinogen Product
• CVS Escalates the Generic Price War
• Dangers of Rogue Online Pharmacies
• Dealing with publication bias using the 'file drawer' scenario.
• Designing effective medications for populations depends on how easy it is to diagnose the populations.
• Despite Bailout, Feds Still Have Cash Left for Physicians to Implement Electronic Records
• Diabetes Screening with Hemoglobin A1c
• Disappointing Results
• Disease-risk Data: will be read, but will not be implemented.
• Diuretic Use May be Higher Than People Think
• DNA Therapeutic Prostate Cancer Vaccine: A Three Pronged Approach by Cyto Pulse Sciences
• Does this dosage form really add anything?
• Down's Syndrome Technology Licensed from Stanford University
• Dronedarone will revolutionize treatment of atrial fibrillation patients
• Drug Act
• Drug Marketing Business Model Needs Change
• Drug Marketing Techniques Can Be Both a Risky and a Useful Endeavor
• Drug Marketing Techniques May Be Risking Patient Safety
• Each Country is different...
• Earlier Treatment Just Makes Sense
• Earlier Treatment Just Makes Sense
• Early Findings Need More Study
• Economic Stimulus Package Could Boost Infectious Disease Diagnostics
• Economic Stimulus Versus an Innovation Stimulus - Can We Have Both?
• Economy's impact on healthcare facilities
• Efficacy isn't everything
• Electronic Medical Records (EMR) are poised for takeoff.
• Electronic Specimens Could Be a New Business Model
• Eli Lilly's Personal Medicine Goal
• End of Era: Abbott's Attempt.
• E-perscriptions?? I love it!!
• E-prescriptions are not available in all the Countries.
• ER testing for HIV: does anyone else see a problem with this?
• Erbitux enhances efficacy in MCRC patients
• Erbitux First Line in MCRC? Let's not get carried away.
• Erbitux improves survival in lung cancer
• Erbitux in K ras wild metastatic first line treatment
• Erbitux in Lung Ca- now to predict who will get the skin rash.
• ESBATech's Antibody Fragment for Osteoarthritis: An Interesting Approach that Raises Interesting Questions
• Everyone wins when patients get drugs they are most likely to offer a benefit
• Extensive use of EHRs-ANL Madhavann, Senior Finance & Healthcare Consultant, SRIMEERA ASSOCIATES INC
• Ezetimibe may confer benefit on atherosclerosis
• FDA Approves CSL's RiaSTAP Human Fibrinogen Product
• FDA Guidance on Evaluating CV Risk of Antidiabetic Therapies
• FDA Joins the Genomic Revolution
• FDA Laboratory Developed Test Regulation Called for by Genentech
• FDA Poised to Damage Asthma Pharmacotherapy Advances
• FDA Regulation of Molecular diagnostics
• FDA Should Have Banned LABAs Five Years Ago
• FDA Will Likely Place Additional Restrictions on Some Asthma Drugs
• Feasibility of Group Appointments
• Filler Warnings- Are They Necessary?
• Financial analysis of the Gardasil-for-Guys question
• First Tysabri PML Related Death Since Relaunch Reported Today
• Fourth MS Patient Identified with PML on Tysabri
• Further Inroads in the Treatment of Fibromyalgia
• Future of microRNA molecular test
• Gardasil for selected men only
• Gardasil will most certainly be approved for boys
• Gastric cancer trial: Phase II but may well be "the real deal"
• Gastroparing forms of naproxen and an awakening FDA
• Gene Sequencing Company News
• Gene Sequencing Company Plans Diagnostics Transition
• Gene Sequencing Strategic Agreement
• Gene Sequencing System Returned
• Gene Sequencing System Sales
• Generic drug price war
• Generic heart drugs
• Generics are here to stay
• Genetic Test Recommendations from EGAPP
• Genetic Testing Produces Profit for Myriad Genetics
• Genetic Testing Recommendations from CDC
• Genetic Testing--ready for all of medicine or just a niche service?
• Genetically determined cancer therapy: It will be a wash.
• Genomic Biomarker for Prostate CA
• Genomics and protemics will be future determinants of "individualized " cancer therapy
• Gleevec's (Novartis) other use...
• Global Hospital IT Market Poised for Significant Growth in Next Five Years
• Glossing over the increased cervical cancer occurences
• Good news for CRP assays
• Good prelim data but need to wait for further data
• Google Launches a Personal Health Record (PHR). So What’s Next for Googleplex?
• Google Launches a Personal Health Record (PHR). So What’s Next for Googleplex?
• GOOGLE PLANS FOR PERSONAL HEALTH RECORD ETHICALLY CORRECT
• Government Run Cancer care
• Grasping at straws for the causes of autism
• Great Deal for Exilexis!! I am not sure about BMS
• Great News For NIH
• Great Relieve: not Stroke, only Death and Heart Attack.
• Group appointments have great potential for limited applications.
• Group of 28 Healthcare Stakeholder Organizations Join Together to Promote Reform
• Growth hormone is not the answer.
• Growth hormone therapy for ALS
• GSK to cut sales force , but......
• GSK's Promacta for ITP: a winner1
• GVAX: Why did it fail? Let me list the possible ways......
• Hard enpoints needed for antidiabeticdrug trials.
• He who is without sin can cast the first stone....
• health care costs
• Health Care in America--An Ailing Commodity That Doctors Can't Cure
• Health IT About to Become a Global Force for Change
• Health IT has its own Quality Chasm to Close
• Health IT is the Foundation of the Hospital of the Future according to the Joint Commission
• Health IT may be at Least Near the Front Burner in the new Congress in 2009
• Health IT Represents a Promising Proposal for Cost Savings if Implemented Correctly
• Health IT-Who Saves?
• Healthcare and Health Insurance Costs
• Healthcare Informatics
• HealthCare Initiatives Supports Single-Payer Universal Healthcare System
• Healthcare reform will save American economy: a new, very advanced, form of delusion.
• Heart Assisting Devices: more is not always better.
• Heart Failure Diagnostic Test
• High End Medical Devices and Implants Are Not Immune to This Recession
• Higher Chemodrugs should not be strategy for Leukemia patient
• High-Tech Device Makers Will Be Pressured
• Hitting the target may reduce the use of targeted cancer drugs or not
• HIV Point-of-Care Screening Shows Benefits
• Hospitals Could Face Perfect Storm
• Hospitals' Electronic Records Adoption Rate Even Lower than Thought
• Hospitals' IT Spends-ANL Madhavann, CEO & Mg Director, SRIMEERA ASSOCIATES INC
• How Healthcare Reform Can Fuel Broader Economic Recovery in the U.S.
• How Low Will Patient Volume Go?
• How Should NIH Spend $10B ?
• HPV vaccination: do we have to think twice?
• I warned you. Genetic testing as well as the companies offering them ARE the way of the future!
• If it seems too good to be true...it probably is.
• If That's What Patients Want, It Will Come
• Immunotherapy for cancer, still have ways to go
• Important Revelation with no Sequences.
• In vitro findings unlikely to have a clinical impact
• Inappropriate Antimicrobial Use is Not Only an American Problem
• Increased efficacy may be associated with long term side effects
• Increased use of Zevalin, Bayer ( & by osmosis Bexxar, GSK) in low grade lymphomas
• Indian pharmaceutical Companies Are Attractive For Multinational Companies
• Infection Control Opportunities
• Intermittent hormonal therapy for Prostate Cancer: Is it here yet?
• Is Celebrex Next ?
• Is Collaboration Key to Success in the Tight Glycemic Control Market?
• Is NY wise to pay doctors to contribute clinical data?
• Is Personal Medicine New or Just Good Medicine
• Is Pharma's Head in the Sand??
• It is not so terrible, but...
• IT USUALLY TAKES TWO TO TANGO, MERCK HPV VACCINE EFFECTIVE IN MEN AND BOYS
• It Works, and Illness is Prevented
• It's always what's relative and seldom absolute
• J&J acquired Mentor specializing on "luxury" surgery during economic recession.
• Joint Implants will always be needed
• Judicious use of antimicrobials
• Jupiter Study: impact on Rosuvastatin
• Just because they say so, it ain't necessarily so.....
• Key thoughts.
• K-ras testing will be a reality soon, Bad news for EGFR inhibitors, but good news for Avastin
• Lab Developed Test Strategy, Regulation and Risks
• LABA and the FDA
• LABA daba done?
• LABA's Should Never Be first Line Therapy
• LABAs should never be used alone!
• Lasik, Pharma, and Cataracts...are they recession proof?
• Later Administration of Alvimopan (Entereg, Adolor) Accelerates GI Recovery
• Leadership often comes from local cooperation
• Lens Refiilling
• Lens refilling and accomodation: pros and cons
• Lens Refilling to Restore Accommodation-Too Good to be True?
• Likely approval at some point soon
• Lilly, NO PROBLEM!!
• Linkage of Molecular pathology test results with diagnostic options
• Lipitor sales
• Long expected new breakthrough
• Looking Beyond Consensus
• Looking Beyond the Consensus that Dealmaking is Good
• Maintenance therapy in NSCLC: the jury is still out?
• makes sense
• Many Key Healthcare Players Will See Drop
• McKesson settlement is next step in the demise of AWP
• Medical device manufacturers' organizations reinforce isolated solutions
• Medical Devices are in certain cases Recession Proof
• Medical Devices not immune to recession worries - "We'll See!"
• Medical Devices that Communicate: Great Concept but Insurers Won't Pay
• Medivations's (MDVN) Dimebon - We've Seen This Movie Before
• Medtronic Endeavour Failing to Live Up to Expectations
• Medtronic: chasing the tail.
• Mentor/J&J deal is long overdue
• Miami Site May Succeed in Quick Recruitment of a Study Population
• Millennium's Velcade, truly a blockbuster!
• Mindray Continues to Innovate
• Minimal Impact on Raptiva Usage - It's Good to Not Be the Leader for the Most Reported PML Cases
• Misleading Headline
• Molecular Diagnostics Agreement
• Molecular Diagnostics Fuels Revenue Growth for Genomic Health
• Molecular Markers for Prostate Cancer
• Monogram Revenues Raise
• More information needed
• More is better with Acute Myelogenous Leukemia (AML)
• More is NOT NECESSARILY better in metastatic colorectal carcinoma.
• More may or may not be better in colorectal cancer
• More Than Just Weight Loss: The Role of Bariatric Surgery in Curing Type 2 Diabetes
• More work needs to be done
• MRSA Pre-Screening Effective in Study
• MRSA Test Platform from Smiths Detection
• Multiple Sclerosis Oral Therapy FTY720 By Novartis Reports Positive Head-To-Head Data
• New biomarker panel outperforms current standard for detecting early-stage ovarian cancer - reason for cautious optimism
• New Cervista(tm) HPV Clincial Trials Reoprt Success
• New Details on WMT-CAT Pharmacy Deal
• New drugs that target new mechanisms add a new layer of cost. Will it always be that way?
• New FDA effort takes aim at genomics: Inherent risk to investors
• New FDA Post to Focus on Genomics
• New IOL Technology
• New is Better--that is what Pharma tells us.
• New MRSA Test
• New study confirms already known facts about LABA's
• New Technology for treatment of sepsis
• Nexavar - Vitamin "N" for Solid Tumors???
• NIH Funding Passes Senate
• NNRs are not thr right target for CDS
• No Incentives for e-prescribing for Physicians
• No one will be spared (but some will be affected more than others)
• No Recession for the Electronic Medical Records Market
• No Visible Revenue Synergies in CVS Caremark's Latest Numbers
• Non-Invasive Blood Glucose Monitoring Revisited.
• Non-Invasive Breast Cancer Marker Found
• Non-Invasive Colorectal Test Planned
• Non-Invasive Glucose Test
• Not a Vaccine I would Mandate
• NOT ALL DERMAL FILLERS ARE CREATED EQUAL
• Not in My Practice
• Not only more cases, more severe cases
• Not so fast on Ritalin for all.
• Nothing new
• Obama Backs Personalized Medicine
• Observation only
• Off Label Use Can Be Prevented
• Old product with little value
• One thing I can assure you, patients will in some way, shape, or form; suffer.
• Only a Matter of Time And Only Time Will Tell
• Opening the Pandora's box again?
• Optimizing EGFR targeted treatment in metastatic colorectal cancer
• Oral Treprostinil: An effective medicine hiding in a study with a challenging design?
• Ovarian Cancer Developments
• Ovarian Cancer License Agreement
• Ovarian Cancer License Agreement Expands
• Overuse, under-focus
• Oxybutinin gel will fill a niche in OAB treatment
• P.A. in an Endocrinology Practice
• Pain Relief with Ulcers, Strokes or Heart Attacks: Pick your poison!
• Panitumumab (and thus Erbitux): The Good, the Bad and the Ugly
• Pantech's Intelligent Marketing Appoach Results in Increased Sales
• Parental "choice" against flu vaccine would be unwise
• Patient Education Critical Adjunct to Testing for Disease Risk
• Pediatric well visits at younger ages may be well-suited to group sessions
• Performance enhancing or potential problem?
• Perhaps the proble is not the British but......
• Personal Health Records
• Personal Medicine Not Ready for Prime Time!
• Personalized Medicine Produces Results
• Personalized Medicine: Find a Target Disease Marker and Streamline the Drug Approval Process
• perspective on diabetes treatments
• Pfizer-Wyeth: Increased Scale Could be The Achilles Heel
• Pharma continues consolidation trend with focus on India
• Pharmacogenetics Strikes Again!!
• Pharmacy Groups Oppose First Databank AWP Settlement
• Pharmacy Profits and Wal-Mart
• Physician support for Personal Health Record Platform will be Challenging
• Plavix and Nexium: incomplete data wrongly interpreted.
• Plitidepsin ( Aplidin) helps in PTCL patients
• Point of Care Company Sees Strong 4Q Growth
• Positive reults in Japanese with gastric cancer can be extended to the Western population?
• Potential for ondansetron is in supportive care to cancer patients (CINV and RINV) and post anesthesia (PONV)
• Potential of LABA `444 in the treatment of COPD
• Potential Windfall for Oral Anti-virals, will Pandemic Vaccine Manufacturers get to Benefit?
• Prasugrel: Blockbuster or Bust- FDA approval and Usage in Clinical Practice
• Predicting response to anti-EGFR cancer therapy
• Prescriptions and the Economy: Perhaps Not So Bad
• President Obama Could be Santa Claus for Health IT Companies
• Principal, Horizon Performance Group
• Process changes must take into account health care needs, not health care wants
• Prodesse files with FDA to Market C. difficile Test in US
• Prostate cancer DNA vaccine trial - a necessary step
• Prostate Cancer Genetic Testing - Is it real or is it boutique lab work?
• Prostate Cancer Test Launched
• Que sera sera
• Quest Completes Second Biomarker License from Epigenomics
• Quest Notifies Clients of Inaccurate Vitamin D Tests
• Rainfall unlikely to be direct culprit to the Autism Pandemic
• Rash Predicts Better Outcome With Erbitux; But Will "Rash" Change Patient Care? Probably Not.
• Real-Time observation of molecular reactions
• Recent Information Regarding Heatlhcare IT's Impact on Patient Lives and Costs
• Recession Presents Both Challenges And Opportunities For Small MedTech Companies
• Refractive Cataract Surgery's Holy Grail: Keep it in Sight
• Regenerative Medicine is a Bold Move for Pfizer and Will Require New R&D Organizational Structures
• remember--- IT'S ALL IN THE GENES!!!!
• Remember the frying pan?
• Restraints to success in IT for Healthcare are not IT-related per se.
• Review of “Task force: Colon cancer screening can stop at 75." by Joann Loviglio of the Associated Press
• Risk of linking funding, precaution principle and marketing techniques
• Risk/Benefit is the Answer, Even More Now
• Roche's Tarceva offers a competitor to Lilly's Alimta
• Rosuvastatin in CV risk reduction
• Rosuvastatin in CV risk reduction
• Rosuvastatin in CV risk reduction
• Rotavirus vaccine delivers
• Sales of Infuse product will likely decline with closer scrutiny of off-label use
• Science vs Marketing
• Sequenom Bids for EXACT Sciences
• Sequenom Builds Molecular Diagnostics Test Portfolio
• Sequenom Restates Clinical Trial Data
• Sequenom Study and News
• Sequenom Terminates EXACT Sciences Offer
• Sequenom's Claims Are Worthy But Not Perfect For Prenatal Diagnosis Of Aneuploidy
• seroquel xl a new formulation
• Shadows casted over "to-be" blockbuster drug
• Simvastatin sell will remain as such
• skepticism
• Solar cells - nothing magic about 25%
• Sorafenib (Bayer) in Breast Cancer: Strike 1
• SQI Diagnostics Closes Second Round Stock Placement
• St. John's Wort vs Prozac
• St. John's Wort: As good a s prescription drugs
• Statin Differences
• Stent Oligopoly: bigger stakes, bigger trials.
• Stevia not "approved" by FDA
• stimulants
• Stockpiling flu vaccines at home will never make sense given Americans' sensibilities
• Strategy of treatment in mCRC
• Study Showing the Positive Impact of Health IT Timed Very Auspiciously
• Sublingual fentanyl for cancer related pain
• Successful Collaboration Is Better Than Individual Failure
• Successful health information exchange will occur when barriers formed by competing interests are mitigated through federal mandate and funding
• Sun Pharma - much stronger with acquisitions including Taro
• Surgical Pathology 'Goldrush'
• Systemic mRNA therapy for liver cancer cancer is new direction
• Tamper proof narcotic
• Tamper Proof Narcotic Pain pill? YES
• Tarceva + Avastin Beats Avastin Alone in Adenocarcinoma of the Lung...
• tarceva adds to avastin but avastin doesn't add to tarceva?
• telaprevir takes therapy for HCV to next level
• Teva gaining more control
• Teva is deserving
• Teva's Generic Imitrex commands market of Sumatriptan
• The War for Wireless Domination: Investors Beware
• The Best Buy in a Difficult Economy
• The Big Apple's $60 Million Electronic Medical Record Keeping Experiment
• The Commonwealth Fund Jumps into the Hospital Quality Ratings Business
• The future is here
• The future of healthcare services is bleak
• The future of lens refilling post cataract extraction
• The Goal Is (And Should Be) 100%
• The Hazards of Herbal Self-Medication
• The Initiation of Phase IIb/III Study of Ralfinamide Represents an Exciting Development in the Treatment of Neuropathic Low Back Pain
• The Low Down On LABA's
• The Most Successful Health Care Systems Support Patient Access to Their Health Information
• The nth proof...
• The rash and EGFR response can be helpful
• The Rise of Generics
• The sensitivity and specificity of protein markers for cancer diagnostics
• The TKI's are building on their success
• The trial will go well, but what are we trying to achieve?
• The vaccine approach to cancer has yet to succeed
• There is still hope for Takeda's antisepsis drug, TAK-242
• They are already doing it.
• Thiazide Diuretics Clearly Linked to Diabetes
• This is not a study!
• This strategy is running out of steam.
• Throwing out the baby with the bathwater
• Thyroid cancer: When it rains it pours
• Treat African Violets not Bacillus anthracis
• Treatin Both Partners for Highest Protection
• Trial set to fail?
• UCB's Vimpat (lacosamide) receives FDA approval
• UNINTENED RESULTS
• Upcoming Multiple Sclerosis Therapeutics: Hope, Risk, and Opportunities
• US Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommendations do not support rapid increase in diagnostic testing based on available evidence and methodologies
• Use of Antipsychotics in Children Poses Risks of Adverse Effects
• Use of Crofelemer
• Use of drugs to enhance mental functioning
• Vaccinate smokers?? what is the agenda and the employer of "The Advisory Committee on Immunization Practices."
• Vaccine for prostate cancer fails
• Vandetanib (Astra Zeneca): too long at the "Fair?"
• Vimpat approved ONLY for adjunctive therapy of epilepsy
• Walgreens buys McKesson Specialty Pharmacy: A Win-Win Deal
• We must hit the cancer target by genetics or whatever technique
• WellPoint Pilot Program May Have Unintended Costs and Create Regulatory Backlash
• What impact economic recession will have on the market for medical devices?
• When being selective, targeted therapy will work
• When Your Neighbor Takes an Antibiotic, So Do You
• Who Benefits/Is At Risk Re: Slowing Growth in Healthcare Costs?
• Who can tolerate these doses and for how long?
• Who Wll Certify the Providers?
• Why hasn't EHR been adopted faster
• Why is the risk of colorectal cancer not higher in Asians?
• Why the doctor can't see you now
• Widespread Health IT Gets "Thumbs Up" from the Green Eyeshade Guys at the CBO
• Wild speculation
• Will Alemtuzumab Be A Revolutionary Treatment For Multiple Sclerosis?
• Will contact lens solutions cost more to ship and store?
• Will J&J's new one-day lens effect the one-day market?
• Without therapeutics, genetic disease diagnostics have limited use
• Worry? No Prepare for the inevitable? Yes
• wrinkle fillers
• Yes, Smaller Populations for Targeted drugs, but Pharma/Biotech AND Patients Win
• Your doctor doesn't get a flu shot WHY????